Europe Medical Cannabis Market Size, Share & Trends Analysis Report By Product Type (Flowers, Concentrates, Topicals & Transdermal Formulations, Oils & Tinctures, Other Product Types), By Application (Oncology, Chronic Pain Management, Mental Health Management, Neurological Disease Management, Other Applications), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Country (U.K., Germany, France, Italy, Russia, Nordic, Benelux, Rest of Europe) Forecasts, 2026-2034

Europe Medical Cannabis Market Size

The Europe Medical Cannabis Market size was valued at USD 4.04 billion in 2025 and is projected to grow from USD 4.80 billion in 2026 to reach USD 19.75 billion by 2034, growing at a CAGR of 18.9% during the forecast period 2026–2034.

Medical cannabis, also known as medical marijuana, is a herbal medication derived from Cannabis plants used to treat specific symptoms or diseases, such as cancer, chronic pain, and psychiatric disorders. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main cannabinoids extracted from this plant that provide medicinal benefits. The market for medical cannabis is expanding because of rising chronic disease prevalence and consumer acceptance of cannabis-based medicines.

It is anticipated that the advancement of medicinal cannabis will fuel the development of this industry over the coming years through clinical trials and judgments made by regulatory agencies in developed countries. In addition, it is anticipated that over the forecast period, the status of medicinal cannabis will improve because of clinical trials and decisions taken by regulatory agencies in developed countries. But the market is constrained by a dearth of knowledge about the advantages of medical marijuana and strict regulatory requirements.

Europe Medical Cannabis Market Segmentation Analysis

By Product Type

The Europe Medical Cannabis Market is segmented into Flowers, Concentrates, Topicals & Transdermal Formulations, Oils & Tinctures, and Other Product Types. Flowers include dried cannabis products used under regulated medical programs, while concentrates contain higher concentrations of cannabinoids and are used in selected pharmaceutical and therapeutic formulations. Topicals & transdermal formulations provide localized or systemic delivery through the skin, whereas oils and tinctures offer controlled administration and flexible dosing. Oils & Tinctures represent a major product category in Europe, supported by their ease of administration, dosing flexibility, and suitability for patients requiring consistent cannabinoid delivery.

Increasing availability of regulated medical cannabis products, expanding pharmaceutical-grade formulations, growing patient access, and improvements in extraction and formulation technologies are supporting demand across product categories. Flowers continue to maintain demand in markets where regulated medical use permits their prescription, while concentrates and advanced formulations are gaining attention as manufacturers focus on standardized cannabinoid concentrations and controlled delivery. Increasing regulatory acceptance, clinical research, and expansion of medical cannabis programs across European countries are expected to support continued product diversification.

Request Customizationto receive a tailored report.

By Application

The Europe Medical Cannabis Market is segmented into Oncology, Chronic Pain Management, Mental Health Management, Neurological Disease Management, and Other Applications. Oncology applications include supportive management of symptoms associated with cancer and its treatment, while chronic pain management represents an important application because medical cannabis is increasingly considered for selected persistent pain conditions. Mental health management includes selected applications involving anxiety and other conditions, while neurological disease management covers conditions such as epilepsy, multiple sclerosis, and related neurological disorders. Other applications include additional therapeutic areas where cannabis-based medicines may be prescribed under applicable clinical and regulatory frameworks.

Chronic Pain Management is a major application area, supported by the high burden of chronic pain and increasing interest in alternative treatment options. Oncology also represents a significant application because cannabinoid-based medicines can be used to help manage symptoms such as treatment-related nausea, appetite loss, and pain. Neurological Disease Management is gaining importance as research and clinical experience expand around epilepsy, multiple sclerosis, and other neurological conditions, while interest in Mental Health Management is increasing alongside research into cannabinoid-based therapies. Continued clinical research, physician awareness, and expansion of regulated prescribing pathways are expected to support application growth across Europe.

By Distribution Channel

The Europe Medical Cannabis Market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies. Hospital pharmacies distribute prescribed medical cannabis products within healthcare institutions and are particularly relevant for patients receiving specialized or supervised treatment. Drug Stores & Retail Pharmacies provide access to prescription medical cannabis in countries where pharmacy-based distribution is permitted, while Online Pharmacies offer digital ordering and delivery capabilities where legally authorized. Hospital and retail pharmacies represent important channels because medical cannabis distribution in several European markets operates through regulated pharmaceutical networks. :contentReference[oaicite:4]{index=4}

Drug Stores & Retail Pharmacies are expected to remain an important distribution channel as medical cannabis programs expand and more patients obtain products through established pharmaceutical networks. Online Pharmacies are gaining opportunities from increasing digital healthcare adoption, e-pharmacy development, and demand for convenient prescription fulfillment, although their role remains dependent on national regulations. Hospital pharmacies continue to support clinically supervised treatment and specialized patient care. Increasing regulatory clarity, expansion of prescription-based access, digitalization of healthcare services, and development of structured medical cannabis supply chains are expected to support growth across distribution channels in Europe.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The Europe medical cannabis market is segmented by country into Germany, the Netherlands, the U.K., and the Rest of Europe. Germany dominates the country market and is expected to grow at a CAGR of 20.5% during the forecast period.

Germany is the largest European producer of medicinal cannabis, and it is anticipated to continue to dominate the market during the projection period. More than treble the 3,000 kilograms imported in 2018, Germany imported 6,500 kilograms of cannabis flowers in 2019 to be distributed to patients in pharmacies. Eight hundred sixty-one kilograms of medicinal cannabis flower were used in Italy in 2019, where the plant and other full-spectrum products are legal. Additionally, the Netherlands sold 580 kilograms of flowers domestically and exported 3,370 kilograms of flowers for pharmacies in other EU nations. In 2019 and 2020, it will provide 2,500 kilograms annually under a contract with Germany. Bedrocan, a Dutch company, was the top vendor in Italy.

In the same way, regional regulatory norms are emerging. The Court of Justice of the European Union decided that CBD is not a narcotic in late 2020 and reclassified marijuana from Schedule IV into a less dangerous category. By examining current legislation in the UK, France, and Spain, the market in this region is anticipated to expand. Six more nations declared the legalization of medical cannabis in 2018. In 2020, 17 ongoing clinical trials in Austria, Bulgaria, Denmark, Germany, Hungary, Netherlands, Poland, the UK, Switzerland, and Spain examined the effectiveness of cannabis and cannabinoid therapies against ailments.

List of Key and Emerging Players in Europe Medical Cannabis Market